Study of Novel Treatment Combinations in Patients With Lung Cancer
← catalyst calendarNCT05633667 · readout ≤ 1,137 d
Sponsored by Gilead Sciences (industry) · GILD — their whole pipeline →. With Arcus Biosciences, Inc..
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
192actual
Sites
89
Countries
Brazil, Hong Kong, Israel +5
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-16 | actual | When the study began enrolling |
| Primary completion | Sep 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lung Cancer
- Advanced or Metastatic Non-Small-Cell Lung Cancer
- Resectable Non-Small-Cell Lung Cancer
Interventions
- Drug: Zimberelimab (ZIM) — also filed as AB122, GS-0122
- Drug: Domvanalimab (DOM) — also filed as AB154, GS-0154
- Drug: Sacituzumab govitecan-hziy (SG) — also filed as GS-0132, IMMU-132
- Drug: Etrumadenant (ETRUMA) — also filed as AB928, GS-0928
- Drug: Carboplatin
- Drug: Cisplatin
- Drug: Pemetrexed
- Drug: Paclitaxel
- Drug: Nab-paclitaxel
- Drug: Docetaxel
- Drug: Nivolumab
Primary outcomes
what the primary-completion date above is the date OFSubstudies 01 and 02: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
measured Up to 5 years
Substudy 03: Complete Pathological Response (pCR) Rate
measured Up to 5 years
Permalink · GILD's whole pipeline · Catalyst calendar · Every registered study · What changed